Our Founder
Nina Kilbride on building Cureledger since 2015: financial-grade rare disease data marketplaces, AI that can finally use longitudinal patient data, and privacy as core design.
Cureledger was started by Nina Kilbride, a rare disease mom who is also an experienced attorney and Series 65-qualified legal software engineer. Nina practiced law in Raleigh-Durham and saw firsthand how the existing system of drug development works. When she had a child with PKU, it became clear how that system left behind people with rare but potentially treatable disorders, while creating incentives to keep profitable common disorders like obesity common.
Nina taught herself to code and has been building since 2015 with a specific vision: financial-grade data marketplaces for rare disease that enable an army of AI agents to do what existing drug development systems cannot. Spend the time to analyze the data. Generate and test hypotheses across rare disease data sets. The missing link is the data source and sovereignty. HIPAA controls a portion of the data relevant for modern research. The remainder sits in an unregulated wild west of value extraction.
It is hard work to have a rare disease. It is an extra job to build an ultra-rare dataset with longitudinal value. Patients and families deserve to see the upside. Cureledger is the system that enables that, with privacy protection as its core design principle.
It is what Nina wishes her family had, and what she is building for every rare disease family.